Piramal Pharma’s consumer healthcare revenue rises 15% in Q1 FY27
Piramal Pharma reported Q1 FY27 revenue of ₹2,270 crore, up 17%, while consumer healthcare grew 15% to ₹347 crore. The company credited power brands and disciplined investment, while flagging volatility in solvent, freight, plastic and petroleum-linked input costs.
Piramal Pharma reported Q1 FY27 revenue growth of 17% to ₹2,270 crore, with consumer healthcare up 15% to ₹347 crore. The company cited power brands and disciplined investment, while managing volatile solvent, transport, plastic and petroleum-linked input costs.
Why this matters
The result follows Piramal Pharma’s target of mid-teen FY27 growth through organic expansion and its earlier Q1 update showing a narrower loss as consumer-health e-commerce rose 40%.
Retail-company signals are accelerating, up 253440% QoQ.
Also reported by
- The Hindu BusinessLine — 1h after first sighting